The application is based on the successful outcome of the pivotal US Phase 3 ConfIdeS trial in highly sensitized patientsImlifidase is an enzyme that rapidly and efficiently cleaves all types ...

Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced the submission of a Biologics License ...

All year long, these moments captivated the public, demonstrated dangerous trends, and pushed research and innovation forward ...

For over 50 years, Jerome Lewis helped build UD's nationally recognized public affairs programs in the Biden School and ...

As California braces for Medicaid cuts, former health secretary to lead new commission in creating plan to protect care ...

Hard to follow the dizzying array of developments out of Washington over the past year? Here are our answers to your pressing ...

Apple® today announced changes impacting iOS apps in Japan to comply with the Mobile Software Competition Act (MSCA). These updates create new options for developers to distribute apps on alternative ...

Ginkgo Bioworks (NYSE: DNA, "Ginkgo"), a provider of research and development services and tools for biological product ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO® (aficamten) has been approved by the China National Medical Products Administration (NMPA) for the treatment of adults with New ...

IonQ's share price surge overstates future revenue opportunities from its products and services. Click here to read an ...

The Patrick J. McGovern Foundation announces $75.8M towards public purpose AI, supporting institutions, communities, and ...